Epizyme Inc (NASDAQ:EPZM): Institutional Investors Aren’t Crazy About It

Epizyme, Inc. (NASDAQ:EPZM) Logo

Sentiment for Epizyme Inc (NASDAQ:EPZM)

Epizyme Inc (NASDAQ:EPZM) institutional sentiment decreased to 1.74 in Q1 2019. Its down -0.44, from 2.18 in 2018Q4. The ratio dropped, as 66 institutional investors increased and opened new holdings, while 38 trimmed and sold equity positions in Epizyme Inc. The institutional investors in our partner’s database now hold: 74.53 million shares, up from 62.73 million shares in 2018Q4. Also, the number of institutional investors holding Epizyme Inc in their top 10 holdings increased from 2 to 4 for an increase of 2. Sold All: 13 Reduced: 25 Increased: 36 New Position: 30.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.25 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

The stock increased 1.33% or $0.18 during the last trading session, reaching $13.72. About 405,437 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has declined 28.37% since July 14, 2018 and is downtrending. It has underperformed by 32.80% the S&P500.

Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on August, 1. They expect $-0.53 EPS, down 26.19 % or $0.11 from last year’s $-0.42 per share. After $-0.39 actual EPS reported by Epizyme, Inc. for the previous quarter, Wall Street now forecasts 35.90 % negative EPS growth.

Foresite Capital Management Ii Llc holds 8.33% of its portfolio in Epizyme, Inc. for 1.49 million shares. Opaleye Management Inc. owns 1.37 million shares or 4.68% of their US portfolio. Moreover, Nea Management Company Llc has 4.42% invested in the company for 6.88 million shares. The California-based Redmile Group Llc has invested 2.81% in the stock. Consonance Capital Management Lp, a New York-based fund reported 3.48 million shares.

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Ratings analysis reveals 83% of Epizyme’s analysts are positive. Out of 6 Wall Street analysts rating Epizyme, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $14 while the high is $28. The stock’s average target of $20.17 is 47.01% above today’s ($13.72) share price. EPZM was included in 10 notes of analysts from February 22, 2019. On Wednesday, February 27 the stock rating was maintained by Roth Capital with “Buy”. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Buy” rating given on Wednesday, February 27 by Oppenheimer. The stock has “Hold” rating by Morgan Stanley on Wednesday, February 27. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Buy” rating by H.C. Wainwright on Monday, June 24. Cowen & Co maintained Epizyme, Inc. (NASDAQ:EPZM) on Friday, June 21 with “Buy” rating. The stock has “Buy” rating by Cowen & Co on Monday, February 25. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, February 27. The stock has “Buy” rating by Citigroup on Wednesday, February 27.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Nasdaq.com which released: “Epizyme (EPZM) Shares Surge More Than 100% YTD: Here’s Why? – Nasdaq” on May 28, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) – Yahoo Finance” published on June 11, 2019, Seekingalpha.com published: “You Should Not Miss Epizyme In 2018 – Seeking Alpha” on August 01, 2018. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Globenewswire.com and their article: “Epizyme Appoints Dr. Shefali Agarwal as Chief Medical Officer – GlobeNewswire” published on July 23, 2018 as well as Seekingalpha.com‘s news article titled: “Epizyme working to lift partial clinical hold on tazemetostat – Seeking Alpha” with publication date: September 05, 2018.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.